• Active, not recruiting

NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM

Updated: Oct 3

KarMMa

bb2121

NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

BlueBird Bio

Relapsed & Refractory Myeloma

NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)

This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.


Sponsor

Celgene

Bristol Myers Squibb


2seventybio

 

ClinicalTrials.gov Identifier: NCT03361748

Official Title: A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

First Posted : December 5, 2017

Click here for details on ClinicalTrials.gov

 

CART - BCMA : National Cancer Institute


Idecabtagene Vicleucel : National Cancer Institute

Idecabtagene Vicleucel : MedlinePlus Drug Information

Anti-BCMA CAR T Cells BB2121

anti-BCMA-CAR-transduced T cells BB2121

BCMA-specific CAR-expressing T lymphocytes BB2121

ide-cel

Abecma

BB2121


Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy

 

bb2121

Bluebird Bio

Idecabtagene Vicleucel

 

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

N Engl J Med: Feb 25, 2021

Click here for details

 

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

N Engl J Med. 2019 May 2

Click here for details

 

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

ASCO Abstract 2020 - 8503

Click here for details

 

1739 Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Program: Oral and Poster Abstracts

Session: 704. Cellular Immunotherapies: Clinical: Poster I

Hematology Disease Topics & Pathways:

Cytokine Release Syndrome, Biological, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Therapies, Lymphoid Malignancies

Saturday, December 11, 2021, 5:30 PM-7:30 PM

Learn more

 

11/04/2021: PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.


Further analyses from the pivotal KarMMa trial in R/R multiple myeloma evaluated baseline predictors of complete responses and outcomes for patients treated with subsequent anti-myeloma therapies, including alternative B-cell maturation antigen (BCMA)-directed therapies, after treatment with Abecma (idecabtagene vicleucel), the first-in-class BCMA-directed CAR T cell therapy


Click here for details.

 

Meeting Abstract | 2021 ASCO Annual Meeting I

Hematologic Malignancies—Plasma Cell Dyscrasia

Journal of Clinical Oncology > List of Issues > Volume 39, Issue 15_suppl >

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.


Learn more

 

OAB-004 - Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed and refractory multiple myeloma: realworld experience


OAB-012 Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival -Bruno Paiva

#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California

IMS 2022 Abstract EBook

https://www.myelomasociety.org/


#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California (themyelomaclinicaltrials.com)

 

- California: University of California San Francisco

- Georgia: Emory University Atlanta

- Massachusetts: Massachusetts General Hospital Boston

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New Jersey: Hackensack University Medical Center

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: UT Southwestern Medical Center Dallas

 

Locations

United States, California

United States, Georgia

United States, Massachusetts

United States, Minnesota

United States, New Jersey

United States, New York

United States, Tennessee

United States, Texas

Canada

Europe

Belgium

France

Germany

Italy

Spain

Asia

Japan

 

RELATED POSTS


NCT03601078: KarMMa-2 - Phase 2 -Efficacy and Safety of bb2121 in relapsed & High Risk Myeloma (RRMM)

A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)

Click here for details


NCT03651128: KarMMa-3 - Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM)

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Click here for details


NCT04196491: KarMMa-4 - Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM)

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)

Click here for details


NCT04855136: KarMMa-7 - Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations (RRMM)

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Click here for details


Posts Archive